Sotgiu S, Barone R, Arru G, Fois M L, Pugliatti M, Sanna A, Rosati G, Musumeci S
Institute of Clinical Neurology, University of Sassari, Sassari, Italy.
Mult Scler. 2006 Oct;12(5):551-7. doi: 10.1177/1352458506070614.
Activated macrophages are major effectors at all stages of lesion formation in multiple sclerosis (MS) brain. Here, we report that the macrophage enzyme chitotriosidase (Chit) is significantly elevated both in plasma and cerebrospinal fluid (CSF) of patients with MS as compared to healthy controls and other neurological patients (P<0.001). Furthermore, the Chit activity in blood significantly associates with the MS clinical course (higher in secondary progressive relative to relapsing-remitting, P=0.01) and the clinical severity as measured by Kurtkze's Expanded Disability Status Scale (P<0.001). Also, we found that Chit activity is compartmentalized in the central nervous system of early MS patients and that its CSF/plasma quotient, in the presence of a preserved albumin quotient, correlates with the extent of future clinical deterioration (r=0.91; P<0.001). These findings confirm that innate immunity, here represented by Chit, is clinically relevant in MS and allows, if confirmed, reconsidering novel MS therapeutic strategies specifically aimed at this branch of the immune response.
活化的巨噬细胞是多发性硬化症(MS)脑损伤形成各个阶段的主要效应细胞。在此,我们报告,与健康对照者和其他神经系统疾病患者相比,MS患者血浆和脑脊液(CSF)中的巨噬细胞酶壳三糖苷酶(Chit)显著升高(P<0.001)。此外,血液中的Chit活性与MS临床病程显著相关(继发进展型相对于复发缓解型更高,P=0.01),并与通过Kurtkze扩展残疾状态量表测量的临床严重程度相关(P<0.001)。而且,我们发现Chit活性在早期MS患者的中枢神经系统中存在分区,并且在白蛋白商保持不变的情况下,其CSF/血浆商与未来临床恶化程度相关(r=0.91;P<0.001)。这些发现证实,以Chit为代表的固有免疫在MS中具有临床相关性,并在得到证实的情况下,允许重新考虑专门针对免疫反应这一分支的新型MS治疗策略。